X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs CIPLA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER CIPLA PFIZER/
CIPLA
 
P/E (TTM) x 34.7 40.5 85.6% View Chart
P/BV x 5.1 3.7 137.0% View Chart
Dividend Yield % 0.7 0.5 146.8%  

Financials

 PFIZER   CIPLA
EQUITY SHARE DATA
    PFIZER
Mar-18
CIPLA
Mar-18
PFIZER/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,365663 356.7%   
Low Rs1,625479 339.2%   
Sales per share (Unadj.) Rs430.3189.0 227.6%  
Earnings per share (Unadj.) Rs78.717.6 447.3%  
Cash flow per share (Unadj.) Rs93.234.0 273.9%  
Dividends per share (Unadj.) Rs20.003.00 666.7%  
Dividend yield (eoy) %1.00.5 190.8%  
Book value per share (Unadj.) Rs586.5176.7 331.9%  
Shares outstanding (eoy) m45.75805.12 5.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.63.0 153.5%   
Avg P/E ratio x25.332.5 78.1%  
P/CF ratio (eoy) x21.416.8 127.6%  
Price / Book Value ratio x3.43.2 105.3%  
Dividend payout %25.417.1 149.0%   
Avg Mkt Cap Rs m91,271459,724 19.9%   
No. of employees `0002.623.6 11.1%   
Total wages/salary Rs m3,14326,901 11.7%   
Avg. sales/employee Rs Th7,484.86,446.1 116.1%   
Avg. wages/employee Rs Th1,195.01,139.4 104.9%   
Avg. net profit/employee Rs Th1,369.1600.0 228.2%   
INCOME DATA
Net Sales Rs m19,685152,193 12.9%  
Other income Rs m1,1433,577 32.0%   
Total revenues Rs m20,828155,769 13.4%   
Gross profit Rs m5,00328,264 17.7%  
Depreciation Rs m66313,228 5.0%   
Interest Rs m41,142 0.4%   
Profit before tax Rs m5,47917,470 31.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m1,8782,501 75.1%   
Profit after tax Rs m3,60114,166 25.4%  
Gross profit margin %25.418.6 136.9%  
Effective tax rate %34.314.3 239.5%   
Net profit margin %18.39.3 196.5%  
BALANCE SHEET DATA
Current assets Rs m24,167108,141 22.3%   
Current liabilities Rs m9,54438,322 24.9%   
Net working cap to sales %74.345.9 161.9%  
Current ratio x2.52.8 89.7%  
Inventory Days Days5597 56.8%  
Debtors Days Days2974 38.6%  
Net fixed assets Rs m9,514109,411 8.7%   
Share capital Rs m4581,610 28.4%   
"Free" reserves Rs m26,375140,682 18.7%   
Net worth Rs m26,832142,292 18.9%   
Long term debt Rs m2536,621 0.1%   
Total assets Rs m36,900228,606 16.1%  
Interest coverage x1,305.516.3 8,012.7%   
Debt to equity ratio x00.3 0.4%  
Sales to assets ratio x0.50.7 80.1%   
Return on assets %9.86.7 145.9%  
Return on equity %13.410.0 134.8%  
Return on capital %20.410.0 205.1%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2251,691 0.0%   
Fx outflow Rs m1,48921,033 7.1%   
Net fx Rs m-1,46630,658 -4.8%   
CASH FLOW
From Operations Rs m3,31814,628 22.7%  
From Investments Rs m-2,383-8,540 27.9%  
From Financial Activity Rs m-1,104-3,855 28.6%  
Net Cashflow Rs m-1692,431 -6.9%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 63.9 20.8 307.2%  
Indian inst/Mut Fund % 7.5 12.2 61.5%  
FIIs % 4.9 23.7 20.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.7 26.2 90.5%  
Shareholders   85,207 161,166 52.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  ABBOTT INDIA  PANACEA BIOTECH  

Compare PFIZER With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 25, 2018 03:37 PM

TRACK PFIZER

PFIZER - TORRENT PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS